BR0008847A - Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas - Google Patents

Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas

Info

Publication number
BR0008847A
BR0008847A BR0008847-1A BR0008847A BR0008847A BR 0008847 A BR0008847 A BR 0008847A BR 0008847 A BR0008847 A BR 0008847A BR 0008847 A BR0008847 A BR 0008847A
Authority
BR
Brazil
Prior art keywords
compounds
methods
pain
antiepileptic
antiepileptic compounds
Prior art date
Application number
BR0008847-1A
Other languages
English (en)
Inventor
Mark Richard Hurtt
Trevor Mundell
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0008847A publication Critical patent/BR0008847A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES ANALGéSICAS QUECOMPREENDEM COMPOSTOS ANTIEPILéPTICOS, EMéTODOS DE USO DAS MESMAS". A presente invençãorefere-se a novas combinações de um ou mais compostosantiepilépticos que demonstram propriedades de alívio de dor, comum ou mais compostos selecionados do grupo que consiste emanalgésicos, antagonistas de receptor de NMDA, NSAIDs ecombinações dos mesmos, e a composições farmacêuticas quecompreendem esses compostos. Verificou-se que a administraçãode compostos antiepilépticos que demonstram propriedades dealívio de dor nessas novas combinações resulta em uma reduçãoaperfeiçoada na freq³ência e gravidade da dor. Acredita-setambém que a incidência de efeitos colaterais indesejáveis podeser reduzida através dessas novas combinações em comparaçãocom o uso de doses mais altas de um tratamento com agente únicopara obter um efeito terapêutico similar. A presente invençãotambém refere-se a métodos de uso de quantidades eficazes dasnovas composições farmacêuticas para tratar dor em mamíferos.
BR0008847-1A 1999-03-10 2000-01-27 Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas BR0008847A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12373999P 1999-03-10 1999-03-10
PCT/US2000/002080 WO2000053225A1 (en) 1999-03-10 2000-01-27 Analgesic compositions comprising anti-epileptic compounds and methods of using same

Publications (1)

Publication Number Publication Date
BR0008847A true BR0008847A (pt) 2001-12-26

Family

ID=22410582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008847-1A BR0008847A (pt) 1999-03-10 2000-01-27 Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas

Country Status (11)

Country Link
US (1) US6451857B1 (pt)
EP (1) EP1161263A1 (pt)
JP (1) JP2002538221A (pt)
AR (1) AR022723A1 (pt)
AU (1) AU3216600A (pt)
BR (1) BR0008847A (pt)
CA (1) CA2359485A1 (pt)
CO (1) CO5150189A1 (pt)
PE (1) PE20001558A1 (pt)
UY (1) UY26052A1 (pt)
WO (1) WO2000053225A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6593368B2 (en) 1997-09-08 2003-07-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU5753900A (en) * 1999-07-02 2001-01-22 Warner-Lambert Company A synergistic combination: gabapentin and pregabalin
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
DE60143671D1 (de) 2001-06-07 2011-01-27 Sang Christine Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
JP4350508B2 (ja) 2001-09-03 2009-10-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6730667B2 (en) * 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
JP2005518411A (ja) * 2002-01-16 2005-06-23 エンド ファーマシューティカルズ インコーポレーテッド 中枢神経系の障害を治療する製薬組成物及び方法
EP1481673A4 (en) * 2002-02-05 2008-09-24 Ajinomoto Kk MEDICAL COMPOSITIONS WITH GABAPENTIN OR PREGABALINE AND N-TYPE CALCIUM CHANNEL ANTAGONIST
BR0307906A (pt) * 2002-02-22 2004-12-21 Warner Lambert Co Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
FR2862875B1 (fr) * 2003-12-02 2006-04-07 Mathey Acoustique Service Preparation pharmaceutique pour le traitement des acouphenes
WO2005102390A2 (en) * 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
KR101380137B1 (ko) 2005-12-22 2014-04-11 뉴론 파마슈티칼즈 에스. 피. 에이. 칼슘 및/또는 나트륨 채널 조절제로서 2-페닐에틸아미노유도체
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) * 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
WO2008077599A1 (en) * 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CA2738468A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
US20160310501A1 (en) * 2013-12-17 2016-10-27 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
CA2951987C (en) 2014-06-16 2017-10-24 Farmaceuticos Rayere, S.A. Pharmaceutical composition that combines an anticonvulsant and a nicotinic acid derivative
MX2015016589A (es) 2015-12-02 2017-06-01 Samuel CHAIT AUERBACH Jaime Composicion oral veterinaria con gabapentina.
US10874626B2 (en) * 2016-04-07 2020-12-29 Nevakar Inc. Formulation for use in a method of treatment of pain
WO2017200700A1 (en) * 2016-05-16 2017-11-23 PixarBio Corporation Methods for treating incisional pain
US11590094B2 (en) 2017-09-28 2023-02-28 Nevakar Injectables Inc. Fixed dose combination formulations for treating pain
JP7249670B2 (ja) 2017-10-03 2023-03-31 ネヴァカー インジェクテーブルズ インコーポレイテッド アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6593368B2 (en) * 1997-09-08 2003-07-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same

Also Published As

Publication number Publication date
EP1161263A1 (en) 2001-12-12
JP2002538221A (ja) 2002-11-12
CO5150189A1 (es) 2002-04-29
WO2000053225A1 (en) 2000-09-14
AR022723A1 (es) 2002-09-04
CA2359485A1 (en) 2000-09-14
PE20001558A1 (es) 2001-01-28
US6451857B1 (en) 2002-09-17
AU3216600A (en) 2000-09-28
UY26052A1 (es) 2000-08-21

Similar Documents

Publication Publication Date Title
BR0008847A (pt) Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
BR9812162A (pt) Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
BR9909903A (pt) Eficácia máxima de substâncias usadas para melhorar a saúde e bem-estar
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0110420A (pt) Agonistas muscarìnicos
BR0012488A (pt) Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
BR0006024A (pt) Composição para o tratamento de inflamação e dor em mamìferos
BR9914419A (pt) Terapia para melhoria da percepção
CA2893768C (en) Topical preparation for pain relief
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
CL2004000452A1 (es) Uso de un compuesto antiepileptico que contiene propiedades de alivio del dolor y dos o mas compuestos del grupo formado por antagonista del nmda selectivos de subtipo, analgesicos, nsaid, y combinaciones de ellos, para la preparacion de un medicamen
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
Liu et al. Comparative study between three analgesic agents for the pain management during extracorporeal shock wave lithotripsy
JP2021510161A (ja) ウォゴニンで疼痛を治療するための組成物および方法
BR112023000598A2 (pt) Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
RU2085194C1 (ru) Средство для местного применения
BR9914981A (pt) Regime analgésico
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
BR0116373A (pt) Utilização de tienilciclo-hexilamina, produto, e, composições farmacêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A,11A E 12A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.